112 related articles for article (PubMed ID: 36760204)
21. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).
Grain A; Rialland-Battisti F; Chevallier P; Blin N; Dalle JH; Michel G; Dhédin N; Peffault de Latour R; Pochon C; Yakoub-Agha I; Bertrand Y; Sirvent A; Jubert C; Forcade E; Berceanu A; Gandemer V; Schneider P; Bay JO; Rohrlich PS; Brissot E; Paillard C; Plantaz D; Nguyen Quoc S; Gonzales F; Maillard N; Planche L; Baruchel A
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1473-1483. PubMed ID: 35507103
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
Yu ZP; Ding JH; Chen BA; Liu BC; Liu H; Li YF; Ding BH; Qian J
Chin J Cancer; 2010 Nov; 29(11):946-51. PubMed ID: 20979694
[TBL] [Abstract][Full Text] [Related]
25. Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
Andolina JR; Wang YC; Ji L; Freyer DR; Levine JE; Pulsipher MA; Gamis AS; Aplenc R; Roth ME; Harrison L; Cairo MS
Bone Marrow Transplant; 2022 Mar; 57(3):445-452. PubMed ID: 34992254
[TBL] [Abstract][Full Text] [Related]
26. Anti-Relapse effects of donor natural killer cells and IL-2 gene modification on allogeneic hematopoietic stem cell transplantation in acute leukemia.
Xue Z; Gao Y; Wu X
Cancer Biomark; 2020; 29(2):207-219. PubMed ID: 32568180
[TBL] [Abstract][Full Text] [Related]
27. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
Su XH; Yao JF; Zhang GX; He Y; Wei JL; Ma QL; Yang DL; Huang Y; Zhai WH; Liang C; Li G; Chen X; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1024-1030. PubMed ID: 29365394
[No Abstract] [Full Text] [Related]
29. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
[TBL] [Abstract][Full Text] [Related]
30. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
31. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis.
Friedman DN; Hilden P; Moskowitz CS; Suzuki M; Boulad F; Kernan NA; Wolden SL; Oeffinger KC; Sklar CA
Biol Blood Marrow Transplant; 2017 Mar; 23(3):475-482. PubMed ID: 28040534
[TBL] [Abstract][Full Text] [Related]
33. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
Front Immunol; 2022; 13():757002. PubMed ID: 35154096
[TBL] [Abstract][Full Text] [Related]
34. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
35. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
Modi D; Deol A; Kim S; Ayash L; Alavi A; Ventimiglia M; Bhutani D; Ratanatharathorn V; Uberti JP
Bone Marrow Transplant; 2017 Nov; 52(11):1530-1536. PubMed ID: 28869613
[TBL] [Abstract][Full Text] [Related]
36. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
Atsuta Y; Suzuki R; Yamashita T; Fukuda T; Miyamura K; Taniguchi S; Iida H; Uchida T; Ikegame K; Takahashi S; Kato K; Kawa K; Nagamura-Inoue T; Morishima Y; Sakamaki H; Kodera Y;
Ann Oncol; 2014 Feb; 25(2):435-41. PubMed ID: 24399081
[TBL] [Abstract][Full Text] [Related]
37. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
Lee CJ; Kim S; Tecca HR; Bo-Subait S; Phelan R; Brazauskas R; Buchbinder D; Hamilton BK; Battiwalla M; Majhail NS; Lazarus HM; Shaw PJ; Marks DI; Litzow MR; Chhabra S; Inamoto Y; DeFilipp Z; Hildebrandt GC; Olsson RF; Kasow KA; Liesveld JL; Rotz SJ; Badawy SM; Bhatt NS; Yared JA; Page KM; Arellano ML; Kent M; Farhadfar N; Seo S; Hematti P; Freytes CO; Rovó A; Ganguly S; Nathan S; Burns L; Shaw BE; Muffly LS
Blood Adv; 2020 Mar; 4(6):983-992. PubMed ID: 32168378
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
Lou D; Liu L; Yan XQ; Gu FN; Zhang YP; Qin WW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
40. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
